Therapies like selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs), and selective estrogen receptor degraders (SERDs) have markedly enhanced survival outcomes by targeting estrogen signaling, a pivotal factor in tumor proliferation in HR+ breast cancer [4]. The gene discussed is ESR1; the disease is breast carcinoma.